News
News
- NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
01/21/2021 / 08:08 - GlobeNewswire - Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
01/20/2021 / 08:00 - GlobeNewswire - Gilead holds 25.54% of Galapagos shares
01/11/2021 / 22:01 - GlobeNewswire - OXURION to Participate in Upcoming Investor Meetings
01/07/2021 / 08:00 - GlobeNewswire - Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
01/06/2021 / 15:30 - GlobeNewswire - Selvita completes acquisition of Fidelta from Galapagos
01/04/2021 / 22:01 - GlobeNewswire - Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
12/23/2020 / 18:00 - GlobeNewswire - Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)
12/15/2020 / 22:15 - GlobeNewswire - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
12/13/2020 / 00:50 - GlobeNewswire - Galapagos increases share capital through subscription right exercises
12/04/2020 / 22:01 - GlobeNewswire
Real-time